ArticleFrontiers in digital health2026
Integration of a tele-dermatology model for Epidermolysis Bullosa improves patient outreach: a before and after observational study.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A hub-and-spokes model strengthens care for Epidermolysis Bullosa by combining specialized expertise with community clinics. Genetic and genomic diagnostics power personalized treatment, whilst telemedicine improves access and affordability of patient care. This integrated system delivers equitable and patient-centered care, reducing burden and improving outcomes for individuals with rare genetic diseases. Methods: This was a before-and-after observational study conducted at the Centre for Human Genetics in Bangalore, between January 2020 and August 2025. Patients with confirmed or suspected Epidermolysis Bullosa (EB) were referred, either by spoke-level practitioners or family members, to a teleconsultation with specialized dermatologists. Clinical data, including family history, were securely documented, and a multidisciplinary team was engaged when further intervention was required. Continuity of care was facilitated through a HIPAA-compliant mobile application, enabling families to maintain communication and follow-up. The impact of the program was evaluated by analyzing its geographical reach, patient evaluation, and comparative medical costs before and after implementation. Results: Developing a standardized diagnostic framework and care pathways for the heterogeneous genetic condition Epidermolysis Bullosa (EB) across a large geographic region addressed a critical gap in the healthcare system. Within our program, 271 patients were enrolled, comprising EB simplex ( Conclusion: Patient care for Epidermolysis Bullosa has focused beyond economic benefits; the model demonstrates how technology can enhance equity in healthcare delivery. Telemedicine and genomic technologies bridge critical gaps in specialized care, particularly for complex conditions such as EB across wide geographic regions. A centralized diagnostic and care framework across wide geographic regions allows for statistically significant reductions in direct medical costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.